News Focus
News Focus
icon url

DewDiligence

05/01/18 4:22 PM

#218786 RE: DewDiligence #218784

2Q18 or 3Q18 may see ABBV/ENTA overtake GILD for the #1 spot in worldwide HCV sales.
icon url

DewDiligence

07/25/18 4:38 PM

#220192 RE: DewDiligence #218784

GILD 2Q18 results—total HCV sales $1.0B—(-5% QoQ):

http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=2359992

Full-year 2018 guidance tweaked upward due to tax rate.